NCT06010537View on ClinicalTrials.gov

Contrast-enhanced Magnetic Resonance Imaging With Polysaccharide Superparamagnetic Iron Oxide Nanoparticle

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Magnetic Resonance Imaging
Interventions
DRUG

polysaccharide superparamagnetic iron oxide injection

Polysaccharide superparamagnetic iron oxide injection is a magnetic resonance contrast agent.

Trial Locations (1)

453000

Xinxiang Central Hospital, Xinxiang

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY